atherosclerotic cardiovascular disease (ASCVD)
Conditions
Interventions
Experimental group:Atorvastatin (Sumaitone: 20mg Po QN) combined with iluzumab injection (Rebenon: 420 mg sc once a month)
Control group:Atorvastatin (sumetone: 20mg po QN) combined with ezetimibe (episol: 10 mg po QD)
Sponsors
Xiangya Hospital, Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Age from 18 to 85 years old, regardless of gender; 2.According to the 2019 ESC/EAS blood lipid guidelines, the following "very high-risk ASCVD" patients (may be accompanied by moderately elevated triglycerides: TG range: 2.3-5.6 mmol/L, that is, 200-500 mg/dL): (1)Carotid artery ultrasound examination revealed significant plaque; (2)Diabetes patients with target organ damage and >=3 major risk factors [According to the 2019 China Cholesterol Education Program Lipid-lowering therapy to reduce cardiovascular events, experts recommend that risk factors include: age (male >=45 years old or female >=55 years old) ), smoking, low-high-density lipoprotein cholesterol, body mass index >=28kg/m^2, family history of early-onset ischemic cardiovascular disease].
Exclusion criteria
Exclusion criteria: 1.Those who are intolerant of statin drugs, ezetimibe and iloyuumab drugs; 2.Those who have used lipid-lowering drugs 24 weeks ago; 3.Pregnant and lactating women; 4.Mental disorders, unable to express their wishes clearly; 5.Those who are unwilling to receive the initial combined lipid-lowering therapy; 6.Those who are unwilling to cooperate, and those who are deemed unsuitable by the doctor, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Low density lipoprotein cholesterin;Lipoprotein a;Carotid palque(18F-NaF PET CT); | — |
Secondary
| Measure | Time frame |
|---|---|
| Total cholesterol;Triglyceride;High density lipoprotein cholesterol;Non high density lipoprotein cholesterol; | — |
Countries
China
Contacts
Public ContactXia Ke
Xiangya Hospital
Outcome results
None listed